UNSPSC 51281512: Verazide

This classification denotes an antitubercular agent with the molecular formula C15H15N3O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier XO8D6I4I5L, chemically known as 3,4-dimethoxybenzal isonicotinoylhydrazone but more generally known as verazide, which bears U.S. National Institutes of Health Compound Identifier 162228. The European Medicines Agency schedules Verazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00039MIG.

The term VERAZIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). VERAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(OC)CCC(C1)/C=N/NC(=O)C1CCNCC1)C.

UNSPSC 51281512 Verazide, a Commodity code, encompasses naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter medical supplies that state and local governments procure for emergency response, public health, and pharmacy benefit programs. Recent solicitations show state and local buyers sourcing naloxone in bulk quantities for community health initiatives, establishing direct-to-manufacturer prescription channels to improve fulfillment efficiency and cost management, and acquiring medical and first aid supplies for emergency services and healthcare facilities. The issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all posted activity under or near this code in the past six months.

Florida, Texas, Minnesota, and Oregon show recent activity, with MMCAP's multistate cooperative purchasing mechanism extending reach across participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000 with a 5 percent bid discount for certified Small Local Business Enterprises; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products across multiple state and local facilities, weighted 75 percent on price competitiveness; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.